Đánh giá nhanh, không xâm lấn và định lượng về bệnh thần kinh sợi nhỏ ở bệnh nhân nhận hóa trị liệu

Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Lévi F (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18(1):136–147 Johnson SA, Harper P, Hortobagyi GN, Pouillart P (1996) Vinorelbine: an overview. Cancer Treat Rev 22(2):127–142 Verstappen CC, Koeppen S, Heimans JJ, Huijgens PC, Scheulen ME, Strumberg D, Kiburg B, Postma TJ (2005) Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology 64(6):1076–1077 Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F (2006) Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 33(1):15–49 Mileshkin L, Stark R, Day B, Seymour JF, Zeldis JB, Prince HM (2006) Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 24(27):4507–4514 Chaudhry V, Eisenberger MA, Sinibaldi VJ, Sheikh K, Griffin JW, Cornblath DR (1996) A prospective study of suramin-induced peripheral neuropathy. Brain 119(Pt 6):2039–2052 Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA (2006) Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24(19):3113–3120 Argyriou AA, Marmiroli P, Cavaletti G, Kalofonos HP (2011) Epothilone-induced peripheral neuropathy: a review of current knowledge. J Pain Symptom Manag 42(6):931–940 Argyriou AA, Kyritsis AP, Makatsoris T, Kalofonos HP (2014) Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature. Cancer Manag Res 6:135–147 Argyriou AA, Bruna J, Marmiroli P, Cavaletti G (2012) Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol 82(1):51–77 Pike CT, Birnbaum HG, Muehlenbein CE, Pohl GM, Natale RB (2012) Healthcare costs and workloss burden of patients with chemotherapyassociated peripheral neuropathy in breast, ovarian, head and neck, and non-small cell lung cancer. Chemother Res Pract. doi:10.1155/2012/913848 Saad M, Tafani C, Psimaras D, Ricard D (2014) Chemotherapy-induced peripheral neuropathy in the adult. Curr Opin Oncol 26(6):634–641 Argyriou AA, Cavaletti G, Antonacopoulou A, Genazzani AA, Briani C, Bruna J, Terrazzino S, Velasco R, Alberti P, Campagnolo M, Lonardi S, Cortinovis D, Cazzaniga M, Santos C, Psaromyalou A, Angelopoulou A, Kalofonos HP (2013) Voltage-gated sodium channel polymorphisms play a pivotal role in the development of Oxaliplatin induced peripheral neurotoxicity: results from a prospective multicenter study. Cancer 119(19):3570–3577 Rostock M, Jaroslawski K, Guethlin C, Ludtke R, Schröder S, Bartsch HH (2013) Chemotherapy-induced peripheral neuropathy in cancer patients: a four-arm randomized trial on the effectiveness of electroacupuncture. Evid Based Complement Alternat Med. doi:10.1155/2013/349653 Nagashima M, Ooshiro M, Moriyama A, Sugishita Y, Kadoya K, Sato A, Kitahara T, Takagi R, Urita T, Yoshida Y, Tanaka H, Oshiro T, Okazumi S, Katoh R (2014) Efficacy and tolerability of controlled-release oxycodone for oxaliplatin-induced peripheral neuropathy and the extension of FOLFOX therapy in advanced colorectal cancer patients. Support Care Cancer 22(6):1579–1584 Yoshida N, Hosokawa T, Ishikawa T, Yagi N, Kokura S, Naito Y, Nakanishi M, Kokuba Y, Otsuji E, Kuroboshi H, Taniwaki M, Taguchi T, Hosoi H, Nakamura T, Miki T (2013) Efficacy of goshajinkigan for Oxaliplatin induced peripheral neuropathy in colorectal cancer patients. J Oncol. doi:10.1155/2013/139740 Tsukaguchi M, Shibano M, Matsuura A, Mukai S (2013) The protective effects of lafutidine for bortezomib induced peripheral neuropathy. J Blood Med 4:81–85 Liu Y, Zhu G, Han L, Liu J, Ma T, Yu H (2013) Clinical study on the prevention of Oxaliplatin-induced neurotoxicity with guilongtongluofang: results of a randomized, double-blind, placebo controlled trial. Evid Based Complement Alternat Med. doi:10.1155/2013/541217 Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR, Fadul CE, Knox C, Le-Lindqwister N, Gilman PB, Shapiro CL, Alliance for Clinical Trials in Oncology (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 309(13):1359–1367 Ogawa K, Ogawa M, Nishijima K, Tsuda M, Nishimura G (2013) Efficacy of contact needle therapy for chemotherapy-induced peripheral neuropathy. Evid Based Complement Alternat Med. doi:10.1155/2013/928129 Coriat R, Alexandre J, Nicco C, Quinquis L, Benoit E, Chéreau C, Lemaréchal H, Mir O, Borderie D, Tréluyer JM, Weill B, Coste J, Goldwasser F, Batteux F (2014) Treatment of oxaliplatin-induced peripheral neuropathy by intravenous mangafodipir. J Clin Invest 124(1):262–272 Argyriou AA, Velasco R, Briani C, Cavaletti G, Bruna J, Alberti P, Cacciavillani M, Lonardi S, Santos C, Cortinovis D, Cazzaniga M, Kalofonos HP (2012) Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients. Ann Oncol 23(12):3116–3122 Alberti P, Rossi E, Cornblath DR, Merkies IS, Postma TJ, Frigeni B, Bruna J, Velasco R, Argyriou AA, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galiè E, Briani C, Dalla Torre C, Faber CG, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey D, Kerrigan S, Schenone A, Fabbri S, Valsecchi MG, Cavaletti G, CI-PeriNomS Group (2014) Physician-assessed and patientreported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. Ann Oncol 25(1):257–264 Cavaletti G, Cornblath DR, Merkies IS, Postma TJ, Rossi E, Frigeni B, Alberti P, Bruna J, Velasco R, Argyriou AA, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galiè E, Briani C, Dalla Torre C, Faber CG, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey D, Kerrigan S, Schenone A, Fabbri S, Valsecchi MG, CI-PeriNomS Group (2013) The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol 24(2):454–462 Krøigarda T, Schrøderb HD, Qvortrupc C, Eckhoffc L, Pfeifferc P, Gaista D, Sindrupa SH (2014) Characterization and diagnostic evaluation of chronic polyneuropathies induced by oxaliplatin and docetaxel comparing skin biopsy to quantitative sensory testing and nerve conduction studies. Eur J Neurol 21:623–629 Griffith KA, Couture DJ, Zhu S, Pandya N, Johantgen ME, Cavaletti G, Davenport JM, Tanguay LJ, Choflet A, Milliron T, Glass E, Gambill N, Renn CL, Dorsey SG (2014) Evaluation of chemotherapy-induced peripheral neuropathy using current perception threshold and clinical evaluations. Support Care Cancer 22:1161–1169 Smith AG, Howard JR, Kroll R, Ramachandran P, Hauer P, Singleton JR, McArthur J (2005) The reliability of skin biopsy with measurement of intraepidermal nerve fiber density. J Neurol Sci 228(1):65–69 Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A, Bernardi L, Valensi P, Toronto Diabetic Neuropathy Expert Group (2010) Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 33(10):2285–2293 Thaisetthawatkul P, Fernandes Filho JAM, Herrmann DN (2013) Contribution of QSART to the diagnosis of small fiber neuropathy. Muscle Nerve 48(6):883–888 Gibbons CH, Illigens BMW, Wang N, Freeman R (2009) Quantification of sweat gland innervation: a clinical–pathologic correlation. Neurology 72(17):1479–1486 Singleton JR, Bixby B, Russell JW, Feldman EL, Peltier A, Goldstein J, Howard J, Smith AG (2008) The Utah Early Neuropathy Scale: a sensitive clinical scale for early sensory predominant neuropathy. J Peripher Nerv Syst 13(3):218–227 Schwarz PE, Brunswick P, Calvet JH (2011) EZSCAN a new tool to detect diabetes risk. Br J Diabetes Vasc Dis 11(4):204–209 Casellini CM, Parson HK, Richardson MS, Nevoret ML, Vinik AI (2013) Sudoscan, a noninvasive tool for detecting diabetic small fiber neuropathy and autonomic dysfunction. Diabetes Technol Ther 15(11):948–953 Freedman BI, Bowden DW, Smith SC, Xu J, Divers J (2014) Relationships between electrochemical skin conductance and kidney disease in Type 2 diabetes. J Diab Complic 28(1):56–60 Chizmadzhev YA, Indenbom AV, Kuzmin PL, Galichenko SV, Weaver JC, Potts RO (1998) electrical properties of skin at moderate voltages: contribution of appendageal macropores. Biophys J 74(2 Pt 1):843–856 Smith AG, Lessard M, Reyna S, Doudova M, Singleton JR (2014) The diagnostic utility of Sudoscan for distal symmetric peripheral neuropathy. J Diabetes Complicat 28(4):511–516 Boyette-Davis JA, Eng C, Wang XS, Cleeland CS, Wendelschafer-Crabb G, Kennedy WR, Simone DA, Zhang H, Dougherty PM (2012) Subclinical peripheral neuropathy is a common finding in colorectal cancer patients prior to chemotherapy. Clin Cancer Res 18(11):3180–3187 Antoine JC, Camdessanché JP (2007) Peripheral nervous system involvement in patients with cancer. Lancet Neurol 6(1):75–86 Argyriou AA, Briani C, Cavaletti G, Bruna J, Alberti P, Velasco R, Lonardi S, Cortinovis D, Cazzaniga M, Campagnolo M, Santos C, Kalofonos HP (2013) Advanced age and liability to Oxaliplatin-induced peripheral neuropathy: post hoc analysis of a prospective study. Eur J Neurol 20(5):788–794